Soluble tumor necrosis factor receptor I (sTNFRI) as a prognostic factor in melanoma patients in Slovene population

• Published in: Pflügers Archiv Vol. 440; no. 5 Suppl; pp. R61 - R063
• Main Authors: Galvani, V, Pretnar Hartman, K, Rupreht, R R, Novaković, S, Stabuc, B, Ocvirk, J, Menart, V, Gaberc Porekar, V, Stalc, A, Rozman, P, Curin Serbec, V
• Format: Journal Article
• Language: English
• Published: Germany 2000
• Subjects: Antigens, CD - metabolism; Carcinoma - metabolism; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Melanoma - metabolism; Melanoma - secondary; Ovarian Neoplasms - metabolism; Prognosis; Receptors, Tumor Necrosis Factor - metabolism; Receptors, Tumor Necrosis Factor, Type I; Slovenia; Solubility; Slovenia
• ISSN: 0031-6768; 1432-2013
• DOI: 10.1007/s004240000007

Tumor necrosis factor alpha (TNF-alpha) and its receptors (TNFRI and TNFRII) which exist in soluble form as a product of cleavage of the extracellular domain of membrane integrated receptors, still rise debate about their importance. It was reported that TNF-alpha has numerous actions in diseases such as inflammation, autoimmunity, infectious diseases, septic shock and many types of cancer [1, 2]. Several authors have reported the significance of sTNFRI level in serum of cancer patients [3, 4]. This study was performed in collaboration with the Institute of Oncology of Slovenia. At least two different mouse monoclonal antibodies (MAbs) against human sTNFRI have been prepared to obtain a sensitive and reliable sandwich ELISA. It was compared with commercially available R&D and Endogen ELISAs for the determination of sTNFRI. Groups of patients with different stages of melanoma and epithelial ovarian carcinoma were tested and their clinical records were reexamined. Levels of sTNFRI were measured and compared with the normal serum levels of sTNFRI.